Michelle Dipp is the Co-Founder and Managing Partner at the healthcare technology equity firm Biospring Partners.
Michelle has served as a Board member of Abzena (a Biospring portfolio company) since 2020.
Michelle has over a decade of experience investing in life sciences at Longwood Fund and General Atlantic and has held various Board positions including at Gingko BioWorks, PathAI and Immunocore.
Michelle previously held senior business development roles at GlaxoSmithKline. She currently serves on the Board of the non-profits Life Science Cares, and the Women’s Foundation of Boston.
Michelle holds a Bachelor of Medicine and Bachelor of Surgery from The University of Oxford Medical School, UK and a Ph.D. in Physiology and Pharmacology from The University of Oxford, where she also undertook post-doctoral research in the Department of Physiology at the John Radcliffe Hospital.